EPISODE · Apr 6, 2026 · 13 MIN
Apr 05, 2026 | Lilly Foundayo vs Novo Oral Wegovy Launch War; Trump Signs 100% Pharma Tariff
from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group
Trump's 100% tariff on patented drugs reshapes pharmastrategy—tiered exemptions create winners and losers. Lilly's Foundayo approved; Novo fires back with ORION data showing oral Wegovy's tolerability edge. Plus Biogen-Apellis, Q1's $47B M&A wave, and the first R&Dpipeline contraction in 30 years.visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, pharma tariff, Trump pharmaceutical tariff, Section 232, Foundayo, orforglipron, Eli Lilly, oral GLP-1, Novo Nordisk, oral Wegovy, semaglutide, ORION study, obesity drugs, Biogen, Apellis, CVR, contingent value rights, biopharma M&A, Orca-T, Orca Bio, Blackstone life sciences, R&D pipeline, Citeline, sparsentan, Travere,AXS-05, Axsome, AACR, AAN, Lilly, Merck
What this episode covers
Trump's 100% tariff on patented drugs reshapes pharmastrategy—tiered exemptions create winners and losers. Lilly's Foundayo approved; Novo fires back with ORION data showing oral Wegovy's tolerability edge. Plus Biogen-Apellis, Q1's $47B M&A wave, and the first R&Dpipeline contraction in 30 years.visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, pharma tariff, Trump pharmaceutical tariff, Section 232, Foundayo, orforglipron, Eli Lilly, oral GLP-1, Novo Nordisk, oral Wegovy, semaglutide, ORION study, obesity drugs, Biogen, Apellis, CVR, contingent value rights, biopharma M&A, Orca-T, Orca Bio, Blackstone life sciences, R&D pipeline, Citeline, sparsentan, Travere,AXS-05, Axsome, AACR, AAN, Lilly, Merck
NOW PLAYING
Apr 05, 2026 | Lilly Foundayo vs Novo Oral Wegovy Launch War; Trump Signs 100% Pharma Tariff
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.